CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 950 participants.
Also called NCT02579096
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 950 participants
- Registry
-
NCT02579096
-
- Other papers using this trial's data
- Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout
- Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02579096. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-06 (actual); primary completion 2021-02-01 (actual). Results posted on 2022-01-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
- Condition
- Gout
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- allopurinol capsule, 100-800 mg by mouth once daily
- Intervention (Drug)
- febuxostat tablet 40-120 mg by mouth once daily
- Intervention (Drug)
- Placebo, vehicle control (febuxostat-shaped)
- Intervention (Drug)
- Placebo, vehicle control (allopurinol-shaped)
- Lead sponsor
- VA Office of Research and Development
Record details
- Record id
cardio:ct-nct02579096- Content hash
09e9053fa47d311e59c61bd72d478f499c22fcc702a1cf72af6362a99b1a68be